Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Onward Medical  /  Forum Onward Medical geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel ONWARD MEDICAL BRU:ONWD.BL, NL0015000HT4

  • 4,780 2 mei 2024 16:52
  • +0,020 (+0,42%) Dagrange 4,700 - 4,840
  • 21.528 Gem. (3M) 131,9K

Forum Onward Medical geopend

1.259 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 63 »» | Laatste | Omlaag ↓
  2. Vitavita 10 november 2022 11:30
    ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore
    Walking after Paralysis.

    Data from all nine participants in STIMO trial published in Nature

    Researchers identify specific neurons activated and remodeled by spinal cord stimulation that enable patients to walk

    EINDHOVEN, the Netherlands, LAUSANNE, Switzerland & BOSTON, MA USA - November 10, 2022 – ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported that a new study by scientists at .NeuroRestore, ONWARD’s research partner, has identified the specific neurons that are activated and remodeled by spinal cord stimulation, enabling individuals with spinal cord injury to stand, walk and rebuild their muscles. This discovery marks a fundamental, scientific breakthrough. The study was published yesterday in Nature.

    In the multi-year STIMO study, coordinated by .NeuroRestore’s co-directors – Grégoire Courtine, a neuroscience professor at EPFL and Chief Scientific Officer of ONWARD, and Jocelyne Bloch, a neurosurgeon at Lausanne University Hospital (CHUV) – participants with paralysis due to spinal cord injury underwent targeted epidural electrical stimulation of the area of the spinal cord that controls leg movement. Remarkably, all participants regained motor function and the ability to walk. Three participants in the study pioneered use of an innovative lead developed by ONWARD to specifically target the areas of the spinal cord involved in leg and lower trunk movement with the intent to facilitate faster and more effective recovery of motor function.

    The scientists believe it is crucial to understand exactly how neuronal reorganization occurs to develop more effective treatments and improve the lives of as many people as possible. The press release by EPFL can be found here.

    “The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis. As a result of this study and its accompanying scientific breakthrough, ONWARD and its research partners have learned precisely where to place the epidural lead and how to program stimulation to facilitate walking,” said Dave Marver, CEO of ONWARD. “This important work is enabling us to develop a therapy for people with spinal cord injury that aims to be precise, repeatable, and scalable.”
  3. Vitavita 10 november 2022 12:21
    snel vertaald...

    ONWARD's onderzoekspartner .NeuroRestore publiceert baanbrekend artikel over het identificeren van neuronen die het lopen herstellen na verlamming

    Data van alle negen deelnemers in STIMO-studie gepubliceerd in Nature

    Onderzoekers identificeren specifieke neuronen die worden geactiveerd en opnieuw gemodelleerd door stimulatie van het ruggenmerg, waardoor patiënten kunnen lopen

    EINDHOVEN, Nederland, LAUSANNE, Zwitserland & BOSTON, MA USA - 10 november 2022 – ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën ontwikkelt om beweging, onafhankelijkheid en gezondheid te herstellen bij mensen met een dwarslaesie ( SCI), meldde vandaag dat een nieuwe studie door wetenschappers van .NeuroRestore, de onderzoekspartner van ONWARD, de specifieke neuronen heeft geïdentificeerd die worden geactiveerd en geremodelleerd door stimulatie van het ruggenmerg, waardoor personen met een dwarslaesie kunnen staan, lopen en hun spieren weer kunnen opbouwen. Deze ontdekking markeert een fundamentele, wetenschappelijke doorbraak. Het onderzoek is gisteren gepubliceerd in Nature.

    In de meerjarige STIMO-studie, gecoördineerd door de mededirecteuren van .NeuroRestore – Grégoire Courtine, hoogleraar neurowetenschappen bij EPFL en Chief Scientific Officer van ONWARD, en Jocelyne Bloch, neurochirurg in het Lausanne University Hospital (CHUV) – deelnemers met verlamming als gevolg van dwarslaesie onderging gerichte epidurale elektrische stimulatie van het gebied van het ruggenmerg dat de beenbeweging regelt. Opmerkelijk was dat alle deelnemers de motorische functie en het vermogen om te lopen terugkregen. Drie deelnemers aan het onderzoek waren pioniers in het gebruik van een innovatieve lead die door ONWARD is ontwikkeld om zich specifiek te richten op de gebieden van het ruggenmerg die betrokken zijn bij been- en lagere rompbewegingen met de bedoeling een sneller en effectiever herstel van de motorische functie te vergemakkelijken.

    De wetenschappers geloven dat het cruciaal is om precies te begrijpen hoe neuronale reorganisatie plaatsvindt om effectievere behandelingen te ontwikkelen en het leven van zoveel mogelijk mensen te verbeteren. Het persbericht van EPFL vindt u hier.

    “De bevindingen die gisteren zijn gepubliceerd, bouwen voort op onze sterke kennisbasis op het gebied van ruggenmergstimulatie om mensen met verlamming te helpen. Als resultaat van deze studie en de bijbehorende wetenschappelijke doorbraak hebben ONWARD en zijn onderzoekspartners precies geleerd waar de epidurale lead moet worden geplaatst en hoe stimulatie moet worden geprogrammeerd om het lopen te vergemakkelijken”, zegt Dave Marver, CEO van ONWARD. “Dit belangrijke werk stelt ons in staat om een therapie te ontwikkelen voor mensen met een dwarslaesie die nauwkeurig, herhaalbaar en schaalbaar is.
  8. Renno54 21 november 2022 13:09
    ONWARD Awarded European Innovation Council Grant to
    Further Develop Brain-Computer Interface Technology;
    Company also Wins First Place in 2022 Brain-Computer
    Interface Awards
    European Innovation Council (EIC) grant is the second such award given to ONWARD
    and its partners to enhance brain-computer interface technology for the benefit of
    people with spinal cord injury
    EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA—November
    21, 2022--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating
    innovative therapies to restore movement, independence, and health in people with spinal cord
    injury (SCI), today announced that the Company has been awarded a second grant from the
    European Innovation Council (EIC) to support the enhancement of an innovative Brain-Computer
    Interface (BCI) technology for restoring mobility and upper limb function in people with spinal cord
    injury.
    Under the EIC Pathfinder funding program, a grant of EUR 3.7 million has been awarded to
    ONWARD and its research partners, including EPFL and CEA-Clinatec. The project is entitled,
    “Auto-Adaptive Neuromorphic Brain Machine Interface (NEMO BMI): Toward Fully Embedded
    Neuroprosthetics.” Under the terms of the grant, ONWARD will receive EUR 1.0 million.
    The NEMO-BMI project will support usability improvements that enable the use of a BCI to support
    upper and lower limb movement. Auto-adaptive algorithms will be developed for brain decoding
    and brain-guided spinal cord stimulation patterns and will then be embedded in miniaturized
    hardware. The goal of the program is to further enhance the BCI technology to make it reliable,
    small, and easy to implant, as well as to improve the BCI’s usability and manufacturability.
    The NEMO-BMI project has started and will complement the ongoing work of the Reverse
    Paralysis project, for which ONWARD and its research partners received an EIC grant of EUR
    3.6 million in June 2022. These proceeds are being used to fund integration between ONWARD’s
    implanted ARC-IM system, which delivers targeted, programmed stimulation of the spinal cord,
    and Clinatec’s WIMAGINE, a fully implantable device approved for chronic use in clinical trials in
    two European countries, which records and decodes the brain's cortical signal to predict a
    person's desired movement intentions. While NEMO-BMI is a separate project from Reverse
    Paralysis, its goal is to build on the Reverse Paralysis framework and incorporate any
    improvements into the joint ONWARD-Clinatec BCI technology platform. The technology
    improvements developed in the NEMO-BMI project will be evaluated independently and then used
    in clinical trials as part of the Reverse Paralysis project.
    2
    ONWARD and Research Partners Win First Place in the 2022 Brain-Computer Interface Award
    Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer
    Interface (BCI) Award. The award was granted to ONWARD and several research partners for
    their submission, “Walking naturally after spinal cord injury using a brain-spine interface.” This
    application focused on the work being done under the Reverse Paralysis project to develop a fully
    implantable brain-computer interface to help people walk more naturally after spinal cord injury
    with the benefit of ONWARD’s ARC Therapy.
    The International BCI Award is one of the top accolades in BCI research and was created to
    recognize outstanding and innovative research in the field of Brain-Computer Interfaces. The
    award is given by the BCI Award Foundation. This year, more than 100 projects were submitted,
    and the jury selected 12 finalists, including teams from Stanford University and the University of
    California San Francisco.
    “The additional funding from EIC as well as the First Place in the 2022 Brain-Computer Interface
    Awards provide strong validation of the important work ONWARD and our partners are doing to
    advance the use of BCI to improve mobility,” said Dave Marver, CEO of ONWARD. "We are
    collaborating with the best in the field to develop and eventually commercialize a BCI platform
    that we hope will optimize the effectiveness of our therapies to restore movement for people living
    with paralysis.”
  9. Vitavita 21 november 2022 13:10
    ONWARD Awarded European Innovation Council Grant to Further Develop Brain-Computer Interface Technology;

    Company also Wins First Place in 2022 Brain-Computer Interface Awards.

    European Innovation Council (EIC) grant is the second such award given to ONWARD and its partners to enhance brain-computer interface technology for the benefit of people with spinal cord injury

    EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA—November 21, 2022--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced that the Company has been awarded a second grant from the European Innovation Council (EIC) to support the enhancement of an innovative Brain-Computer Interface (BCI) technology for restoring mobility and upper limb function in people with spinal cord injury.

    Under the EIC Pathfinder funding program, a grant of EUR 3.7 million has been awarded to ONWARD and its research partners, including EPFL and CEA-Clinatec. The project is entitled, “Auto-Adaptive Neuromorphic Brain Machine Interface (NEMO BMI): Toward Fully Embedded Neuroprosthetics.” Under the terms of the grant, ONWARD will receive EUR 1.0 million.

    The NEMO-BMI project will support usability improvements that enable the use of a BCI to support upper and lower limb movement. Auto-adaptive algorithms will be developed for brain decoding and brain-guided spinal cord stimulation patterns and will then be embedded in miniaturized hardware. The goal of the program is to further enhance the BCI technology to make it reliable, small, and easy to implant, as well as to improve the BCI’s usability and manufacturability.

    The NEMO-BMI project has started and will complement the ongoing work of the Reverse Paralysis project, for which ONWARD and its research partners received an EIC grant of EUR 3.6 million in June 2022. These proceeds are being used to fund integration between ONWARD’s implanted ARC-IM system, which delivers targeted, programmed stimulation of the spinal cord, and Clinatec’s WIMAGINE, a fully implantable device approved for chronic use in clinical trials in two European countries, which records and decodes the brain's cortical signal to predict a person's desired movement intentions. While NEMO-BMI is a separate project from Reverse Paralysis, its goal is to build on the Reverse Paralysis framework and incorporate any improvements into the joint ONWARD-Clinatec BCI technology platform. The technology improvements developed in the NEMO-BMI project will be evaluated independently and then used in clinical trials as part of the Reverse Paralysis project.

    ONWARD and Research Partners Win First Place in the 2022 Brain-Computer Interface Award

    Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award. The award was granted to ONWARD and several research partners for their submission, “Walking naturally after spinal cord injury using a brain-spine interface.” This application focused on the work being done under the Reverse Paralysis project to develop a fully implantable brain-computer interface to help people walk more naturally after spinal cord injury with the benefit of ONWARD’s ARC Therapy.

    The International BCI Award is one of the top accolades in BCI research and was created to recognize outstanding and innovative research in the field of Brain-Computer Interfaces. The award is given by the BCI Award Foundation. This year, more than 100 projects were submitted, and the jury selected 12 finalists, including teams from Stanford University and the University of California San Francisco.

    “The additional funding from EIC as well as the First Place in the 2022 Brain-Computer Interface Awards provide strong validation of the important work ONWARD and our partners are doing to advance the use of BCI to improve mobility,” said Dave Marver, CEO of ONWARD. "We are collaborating with the best in the field to develop and eventually commercialize a BCI platform that we hope will optimize the effectiveness of our therapies to restore movement for people living with paralysis.”

    About Spinal Cord Injury
    Spinal cord injury (SCI) represents a major unmet medical need for which there is no cure. Approximately 7 million people globally have a spinal cord injury, with over 650,000 in the U.S. and Europe alone. The quality of life of people with SCI can be poor, with paralysis and loss of sensation, issues with blood pressure control and trunk stability, increased potential for infection, incontinence, and loss of sexual function. Assistance is required for daily living activities. And SCI is costly, with the average lifetime cost for paraplegia (paralysis of the legs) of $2.5 million and $5 million for tetraplegia (paralysis of all four limbs). Treatments are urgently needed to restore movement and improve quality of life

    About ONWARD Medical
    ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

    ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.

    ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The company has an academic partnership with.NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com.
  13. Vitavita 1 december 2022 19:26
    quote:

    Bonsjoer schreef op 30 november 2022 13:18:

    Watch the latest episode of “ONWARD with Scott Chesney,” where Scott and Dave Marver, CEO of
    @onwdempowered
    , reconnect after eight months to provide a promising update on the company’s progress as it moves towards commercialization.
    youtu.be/xtXUW5MEUQQ
    Dank voor het interview!
  14. WinstPercentage 2 december 2022 19:06
    Volume van 75 stukjes vandaag.. gemiddeld 10.800? stond hier vrij versteld van maar ben ook niet zo bekend met 'Opkomende lokale bedrijven.
    Klopt het dat je in zo'n bedrijf niet short kunt gaan? (Niet dat ik dat zou willen hoor geloof in de technologie die ze aan het uitrollen zijn) en heb dan ook een aankoop order uitgezet van 6,- nu afwachten of ze me gegund worden '')
  17. MicJo 8 december 2022 12:00
    Na even zoeken moet het dit bericht zijn:

    Goede eerste resultaten Onward met studie dwarslaesie

    Door ABM Financial News op 8 december 2022 07:53 | Views: 628

    Goede eerste resultaten Onward met studie dwarslaesie

    (ABM FN) Onward Medical heeft positieve eerste studieresultaten gepresenteerd met een onderzoek in Zwitserland en Canada. Dit bleek donderdag voorbeurs uit een persbericht van het Nederlands-Zwitserse bedrijf.

    Onward presenteerde de eerste tussentijdse resultaten die het behaalde met de behandeling van 10 mensen met een dwarslaesie.

    CEO Dave Marver sprak van "veelbelovende" uitkomsten. Volgens de topman zijn er nu nog maar weinig opties voor de behandeling van mensen met een dwarslaesie en een lage bloeddruk. En de opties die er zijn, zijn niet effectief, volgens Onward. En de behandeling van Onward lijkt dus wel een goede optie te zijn.

    Van alle mensen in de VS en Europa met een dwarslaesie heeft meer dan 40 procent last van een lage bloeddruk, waardoor zij slechts beperkt kunnen deelnemen aan fysieke revalidatieprogramma's.

    Onward heeft op basis van de vandaag gepresenteerde resultaten besloten om in 2023 verder klinisch onderzoek te doen en te starten met Amerikaanse deelnemers.

    Bron: ABM Financial News
1.259 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 63 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

ONWARD MEDICAL Nieuws

  1. 25 apr Minder omzet en groter verlies Onward Medical in 2023
  2. 09 apr Stifel zet koopadvies op Onward Medical
  3. 02 apr Onward Medical dient de novo aanvraag in bij Amerikaanse FDA
  4. 21 mrt Beursblik: KBC Securities verlaagt koersdoel Onward Medical
  5. 21 mrt Onward haalt €20 miljoen op 2
  6. 20 mrt Onward haalt tot 20 miljoen euro op
  7. 18 mrt Systeem Onward doorstaat test
  8. 15 mrt Onward presenteert plannen voor 2024 1
  9. 11 mrt Degroof: goed nieuws FDA voor Onward heeft nog geen invloed op koersdoel
  10. 11 mrt Onward toegelaten tot TAP-programma FDA

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!